JATT grants Eli Lilly 550,000 shares for IL-33 license; contingent on Zura merger

Zura Bio Ltd

JATT granted Eli Lilly 550,000 Class A shares as partial consideration for Lilly licensing an IL-33 compound to Z33, a Zura subsidiary.
Shares issued in a private placement exempt from registration under Section 4(a)(2) of the Securities Act.
Shares subject to staggered lock-up: one-third restricted for 6, 12, and 24 months post-closing, with early release if stock hits $12 for 20 of 30 trading days.
Equity Grant closing contingent on completion of JATT's business combination with Zura Bio.
Lilly entered into a License Agreement with Z33 on December 8, 2022 for the compound.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Zura Bio Ltd entered into Equity Grant Agreement with Eli Lilly and Company valued at JATT to issue and grant to Lilly 550,000 Class A ordinary shares in a private placement transaction (effective 2022-12-08).

Action: entry
Agreement: equity purchase
Counterparty: Eli Lilly and Company
Value: JATT to issue and grant to Lilly 550,000 Class A ordinary shares in a private placement transaction
Effective: 2022-12-08

Exact text from the filing

Concurrently with the execution of the License Agreement, on December 8, 2022, as partial consideration for Lilly entering into the License Agreement with Z33, JATT and Lilly entered into that certain Equity Grant Agreement, pursuant to which JATT agreed to issue and grant to Lilly 550,000 Class A ordinary shares of JATT (the “ Shares ”) in a private placement transaction.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Zura Bio Ltd entered into License, Development and Commercialization Agreement with Eli Lilly and Company valued at License granted regarding intellectual property rights for a certain compound relating to IL-33 (effective 2022-12-08).

Action: entry
Agreement: license
Counterparty: Eli Lilly and Company
Value: License granted regarding intellectual property rights for a certain compound relating to IL-33
Effective: 2022-12-08

Exact text from the filing

Effective on December 8, 2022, Z33 Bio Inc. (“ Z33 ”), an entity controlled by Zura entered into the License, Development and Commercialization Agreement (the “ License Agreement ”) with Eli Lilly and Company (“ Lilly ”), pursuant to which Lilly granted a license to Z33 regarding certain intellectual property rights for a certain compound relating to IL-33 to develop, manufacture and commercialize such compound, subject to the terms and conditions set forth therein.

View on SEC.gov

271 material agreements filed in the last 30 days. Browse all material agreements →

Zura Bio Ltd filing history →

Source: SEC EDGAR

accession 0001104659-22-126265

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.